Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
- |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
0 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the research and development of innovative cancer treatments. The company is focused on developing therapies for pediatric patients, particularly those with rare forms of cancer. Fennec's primary product is sodium thiosulfate, which is being investigated as a potential treatment to prevent hearing loss caused by cisplatin, a common chemotherapy drug. The company aims to improve the quality of life for cancer patients by addressing the side effects of chemotherapy and developing effective and safe treatment options.
|